MA49510A - Formulations orales-mucosales d'isotrétinoïne et procédés d'utilisation correspondants - Google Patents

Formulations orales-mucosales d'isotrétinoïne et procédés d'utilisation correspondants

Info

Publication number
MA49510A
MA49510A MA049510A MA49510A MA49510A MA 49510 A MA49510 A MA 49510A MA 049510 A MA049510 A MA 049510A MA 49510 A MA49510 A MA 49510A MA 49510 A MA49510 A MA 49510A
Authority
MA
Morocco
Prior art keywords
isotretinoin
oral
related methods
mucosal formulations
mucosal
Prior art date
Application number
MA049510A
Other languages
English (en)
Inventor
Siew L Chung
Hock S Tan
Original Assignee
Skyline Biosciences Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Skyline Biosciences Llc filed Critical Skyline Biosciences Llc
Publication of MA49510A publication Critical patent/MA49510A/fr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/20Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/201Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/20Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/20Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/203Retinoic acids ; Salts thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/2027Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
MA049510A 2017-06-29 2018-06-29 Formulations orales-mucosales d'isotrétinoïne et procédés d'utilisation correspondants MA49510A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762526743P 2017-06-29 2017-06-29

Publications (1)

Publication Number Publication Date
MA49510A true MA49510A (fr) 2020-05-06

Family

ID=63036329

Family Applications (1)

Application Number Title Priority Date Filing Date
MA049510A MA49510A (fr) 2017-06-29 2018-06-29 Formulations orales-mucosales d'isotrétinoïne et procédés d'utilisation correspondants

Country Status (14)

Country Link
US (3) US10874607B2 (fr)
EP (2) EP3644961B9 (fr)
JP (1) JP2020526579A (fr)
KR (1) KR20200135931A (fr)
CN (1) CN111032017A (fr)
AU (1) AU2018294318A1 (fr)
CA (1) CA3068310A1 (fr)
EA (1) EA202090164A1 (fr)
IL (1) IL271737A (fr)
MA (1) MA49510A (fr)
MX (1) MX2020000164A (fr)
PH (1) PH12020500032A1 (fr)
SG (1) SG11201912887VA (fr)
WO (1) WO2019006287A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201912887VA (en) 2017-06-29 2020-01-30 Skyline Biosciences Llc Isotretinoin oral-mucosal formulations and methods for using same
DE102019135432A1 (de) * 2019-12-20 2021-06-24 Lts Lohmann Therapie-Systeme Ag Lösliche Rückschicht für OTF
CN113209052B (zh) * 2021-03-16 2022-02-15 深圳市泰力生物医药有限公司 ***二酚自纳米乳口颊膜制剂及其制备方法和用途

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS59232552A (ja) * 1983-06-16 1984-12-27 日東電工株式会社 粘膜包帯
US4678663A (en) * 1984-02-06 1987-07-07 Nuetrogena Corporation Hydroquinone composition having enhanced bio-availability and percutaneous adsorption
JPS63189484A (ja) * 1987-01-30 1988-08-05 Sekisui Chem Co Ltd 口腔粘膜貼付剤用の粘着剤組成物
US4985235A (en) * 1988-08-02 1991-01-15 Kligman Albert M Treatment of periodontoclasia with retinoic acid
US5188817A (en) * 1989-03-27 1993-02-23 Julius Ozick Method of treatment for periodontitis
US6270781B1 (en) * 1999-01-08 2001-08-07 Maxim Pharmaceuticals, Inc. Method and compositions for topical treatment of damaged tissue using reactive oxygen metabolite production or release inhibitors
KR100403699B1 (ko) * 2000-03-17 2003-11-01 주식회사 엘지생활건강 치아 미백용 패취
PT1318791E (pt) 2000-09-22 2004-11-30 Galephar M F Composicao farmaceutica semi-solida de isotretinoina
JP4850346B2 (ja) * 2001-03-15 2012-01-11 救急薬品工業株式会社 粘膜貼付剤
CN1829490A (zh) * 2003-07-01 2006-09-06 托德·迈巴赫 包含治疗剂的薄膜
JP4413665B2 (ja) * 2004-03-19 2010-02-10 救急薬品工業株式会社 口腔内粘膜フィルム剤
US20050281757A1 (en) * 2004-06-17 2005-12-22 Sayed Ibrahim Oral care film
JP2008526856A (ja) * 2005-01-05 2008-07-24 ノバセア インコーポレイティッド 活性ビタミンd化合物またはその模倣体による血栓性疾患の予防
WO2006117803A2 (fr) * 2005-03-14 2006-11-09 Devarajan, Padma, Venkitachalam Systemes d'administration transmucosale de medicaments
US9067082B2 (en) * 2006-07-26 2015-06-30 Ultradent Products, Inc. Dental bleaching compositions having long-term rheological stability and devices, kits and methods that utilize such compositions
US20120046354A1 (en) * 2010-08-18 2012-02-23 Ehrenpreis Eli D Anti-oxidant lozenges for the prevention and treatment of radiation induced mucositis, precancerous lesions, oral cancer and other oral cavity mucosal disorders
US8241661B1 (en) * 2011-06-24 2012-08-14 Fuisz Richard C Biocompatible film with variable cross-sectional properties
US9492426B2 (en) 2011-09-21 2016-11-15 The Texas A&M University System Mycophenolic acid analogues as anti-tumor chemosensitizing agents
US9078925B2 (en) 2012-06-18 2015-07-14 Galephar Pharmaceutical Research, Inc. Pharmaceutical semi-solid composition of isotretinoin
CN103319365B (zh) * 2013-06-05 2015-07-08 中国医学科学院皮肤病研究所 一种异维甲酸酰胺衍生物及其制备方法和应用
RU2016150863A (ru) * 2014-05-29 2018-07-03 Сан Фармасьютикал Индастриз Лимитед Пероральная фармацевтическая композиция изотретиноина
EP3346998A4 (fr) * 2015-08-17 2019-08-28 Sidmak Laboratories (India) PVT. Ltd. Système d'administration de film par voie topique
SG11201912887VA (en) 2017-06-29 2020-01-30 Skyline Biosciences Llc Isotretinoin oral-mucosal formulations and methods for using same

Also Published As

Publication number Publication date
US20200093735A1 (en) 2020-03-26
KR20200135931A (ko) 2020-12-04
CA3068310A1 (fr) 2019-01-03
MX2020000164A (es) 2020-07-22
EA202090164A1 (ru) 2020-05-14
US10813880B2 (en) 2020-10-27
PH12020500032A1 (en) 2020-09-14
US20210244656A1 (en) 2021-08-12
EP3644961A1 (fr) 2020-05-06
AU2018294318A1 (en) 2020-01-30
IL271737A (en) 2020-02-27
EP3960155A1 (fr) 2022-03-02
US10874607B2 (en) 2020-12-29
CN111032017A (zh) 2020-04-17
SG11201912887VA (en) 2020-01-30
JP2020526579A (ja) 2020-08-31
EP3644961B9 (fr) 2021-10-13
EP3644961B1 (fr) 2021-08-04
WO2019006287A1 (fr) 2019-01-03
US20200093734A1 (en) 2020-03-26

Similar Documents

Publication Publication Date Title
MA44524A (fr) Néoantigènes et leurs procédés d'utilisation
MA50359A (fr) Anticorps anti-cd38 et procédés d'utilisation
MA43018A (fr) Anticorps anti-pd1 et procédés d'utilisation
MA50948A (fr) Anticorps et procédés d'utilisation de ceux-ci
MA46566A (fr) Oxystérols et leurs procédés d'utilisation
MA44990A (fr) Polythérapies d'inhibiteurs de hdac et d'inhibiteurs de pd-l1
MA43802A (fr) Matières cellulosiques et procédés de fabrication et d'utilisation de celles-ci
MA42043A (fr) Anticorps anti-ox40 et procédés d'utilisation de ceux-ci
MA41999A (fr) Compositions d'acide obéticholique et procédés d'utilisation
MA46565A (fr) Oxystérols et leurs procédés d'utilisation
MA55097A (fr) Oxystérols et leurs procédés d'utilisation
MA42925A (fr) Anticorps anti-tigit et méthodes d'utilisation
MA41951A (fr) Gènes insecticides et procédés d'utilisation
MA47849A (fr) Anticorps anti-gitr et leurs procédés d'utilisation
MA44740A (fr) Variantes de capsides de virus adéno-associé et leurs procédés d'utilisation
MA45671A (fr) Anticorps antivirus zika et procédés d'utilisation
MA53355A (fr) Anticorps anti-ctla-4 et leurs procédés d'utilisation
MA55776A (fr) Gènes pesticides et procédés d'utilisation
MA51552A (fr) Anticorps anti-ox40 et procédés d'utilisation
MA50956A (fr) Anticorps anti-cd137 et procédés d'utilisation correspondants
MA53235A (fr) Indoles substitués et procédés d'utilisation associés
MA54851A (fr) Oxystérols et leurs procédés d'utilisation
MA42409A (fr) Oxystérols et leurs procédés d'utilisation
MA42979A (fr) Anticorps anti-age et procédés d'utilisation correspondants
MA40921A (fr) Récepteurs antigéniques chimériques anti-cldn et procédés d'utilisation